References
- Huysmans, K.; Lins, R L.; Daelemans, R.; Zachee, P.; De Broe, M E. Hypertension and accelerated atherosclerosis in endstage renal disease. J. Nephrol. 1998, 11, 185–195. [PUBMED], [INFOTRIEVE]
- Kaysen, G A. The microinflammatory state in uremia: causes and potential consequences. J. Am. Soc. Nephrol. 2001, 12, 1549–1557. [PUBMED], [INFOTRIEVE], [CSA]
- Lariviere, R.; Lebel, M. Endothelin-1 in chronic renal failure and hypertension. Can. J. Physiol. Pharm. 2003, 81, 607–621. [CROSSREF]
- Emori, T.; Hirata, Y.; Ohta, K.; Shichiri, M.; Marumo, F. Secretory mechanism of immunoreactive endothelin in cultured bovine endothelial cells. Biochem. Biophys. Res. Commun. 1989, 160, 93–100. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Lariviere, R.; Lebel, M.; Kingma, I.; Grose, J H.; Boucher, D. Effects of losartan and captopril on endothelin-1 production in blood vessels and glomeruli of rats with reduced renal mass. Am. J. Hypertens. 1998, 11, 989–997. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Libby, P.; Ridker, P M.; Maseri, A. Inflammation and atherosclerosis. Circulation 2002, 105, 1135–1143. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Brehm, B R.; Wolf, S C.; Bertsch, D.; Klausser, M.; Wesselborg, S.; Schuler, S.; Schulze-Osthoff, K. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc. Res. 2001, 49, 430–439. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Bosch, J.; Yusuf, S.; Pogue, J.; , et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002, 324, 699–702. [CROSSREF]
- Lewis, E J.; Hunsicker, L G.; Bain, R P.; Rohde, R D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group. N. Engl. J. Med. 1993, 329, 1456–1462. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ruggenenti, P.; Perna, A.; Gherardi, G.; Gaspari, F.; Benini, R.; Remuzzi, G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo italiano di studi epidemiologici in nefrologia (GISEN). Ramipril efficacy in nephropathy. Lancet 1998, 352, 1252–1256. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997, 349, 1857–1863. [CROSSREF]
- Maschio, G.; Alberti, D.; Janin, G.; Locatelli, F.; Mann, J F.; Motolese, M.; Ponticelli, C.; Ritz, E.; Zucchelli, P. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The angiotensin-converting-enzyme inhibition in progressive renal insufficiency study group. N. Engl. J. Med. 1996, 334, 939–945. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Miyazaki, M.; Sakonjo, H.; Takai, S. Anti-atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in Cynomolgus monkeys fed a high-cholesterol diet. Br. J. Pharmacol. 1999, 128, 523–529. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Churchill, D A.; Siegel, C O.; Minor, S T.; West, M S.; Raizner, A E. Enalapril in the prevention of restenosis following intracoronary intervention in a swine model. Coron. Artery Dis. 1993, 4, 461–467. [PUBMED], [INFOTRIEVE]
- Bravo, R.; Somoza, B.; Ruiz-Gayo, M.; Gonzalez, C.; Ruilope, L M.; Fernandez-Alfonso, M S. Differential effect of chronic antihypertensive treatment on vascular smooth muscle cell phenotype in spontaneously hypertensive rats. Hypertension 2001, 37, E4–E10. [PUBMED], [INFOTRIEVE]
- Lam, J Y.; Lacoste, L.; Bourassa, M G. Cilazapril and early atherosclerotic changes after balloon injury of porcine carotid arteries. Circulation 1992, 85, 1542–1547. [PUBMED], [INFOTRIEVE]
- Teng, J.; Fukuda, N.; Suzuki, R.; , et al. Inhibitory effect of a novel angiotensin II type 1 receptor antagonist RNH-6270 on growth of vascular smooth muscle cells from spontaneously hypertensive rats: different anti-proliferative effect to angiotensin-converting enzyme inhibitor. J. Cardiovasc. Pharmacol. 2002, 39, 161–171. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wilson, D P.; Saward, L.; Zahradka, P.; Cheung, P K. Angiotensin II receptor antagonists prevent neointimal proliferation in a porcine coronary artery organ culture model. Cardiovasc. Res. 1999, 42, 761–772. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Jaffa, A A.; Durazo-Arvizu, R.; Zheng, D.; , et al. Plasma prekallikrein: a risk marker for hypertension and nephropathy in type 1 diabetes. Diabetes 2003, 52, 1215–1221. [PUBMED], [INFOTRIEVE]
- Velarde, V.; Ullian, M E.; Morinelli, T A.; Mayfield, R K.; Jaffa, A A. Mechanisms of MAPK activation by bradykinin in vascular smooth muscle cells. Am. J. Physiol. 1999, 277, C253–C261. [PUBMED], [INFOTRIEVE]
- Brehm, B R.; Wolf, S C.; Freudenberg, J.; Friedmann, F.; Heinle, H.; Schulze-Osthoff, K. Modulation of the beta-adrenergic receptor system of vascular smooth muscle cells in vitro and in vivo by chronically elevated endothelin-1 levels. Biochem. Pharmacol. 2002, 63, 1361–1369. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Brehm, B R.; Klaussner, M.; Wolf, S C. Chronic elevated endothelin-1 concentrations regulate mitogen-activated protein kinases ERK 1 and ERK 2 in vascular smooth muscle cells. Clin. Sci. (Lond) 2002, 103 (Suppl 48), 137S–140S. [CSA]
- Murakoshi, N.; Miyauchi, T.; Kakinuma, Y.; , et al. Vascular endothelin-B receptor system in vivo plays a favorable inhibitory role in vascular remodeling after injury revealed by endothelin-B receptor-knockout mice. Circulation 2002, 106, 1991–1998. [PUBMED], [INFOTRIEVE], [CROSSREF]